Tharimmune, Inc.

We are pleased to share that CEO Randy Milby is presenting in-person at the ThinkEquity Conference in NYC today at 10AM ET | Lotus Suite West. Webcast available to registered attendees. www.tharimmune.com #BusinessUpdate

Hillstream BioPharma (Nasdaq: HILS) is thrilled to announce a corporate name change to Tharimmune, Inc! The company’s common stock will trade on Nasdaq under a new ticker symbol, THAR (Nasdaq: THAR), effective as of Monday, September 25, 2023. "Over the past few months, we have made significant progress in shifting the focus of the Company to align with our future vision to impact patients in serious need of new treatment options. Our new name, dedicated to the courage of all people diagnosed with diseases of high unmet need, aligns with this focus as we shift into a patient-centric organization striving towards developing impactful and accessible products,” said Randy Milby, Chairman and CEO of Tharimmune, Inc. Tharimmune is also progressing towards acquiring a clinical stage asset, TH104, with a recently approved IND. We expect to close the acquisition in the fourth quarter as well launch and complete a phase 1 pharmacokinetic trial by year-end. Read here for more details: https://bit.ly/3PPATAj #BusinessUpdate #Biotech #Oncology

In case you missed it: Hillstream BioPharma CEO Randy Milby joined Benzinga's #AllAccess show last week to discuss current developments in the company’s pipeline, our lead program HSB-3215, and what’s on the horizon. Watch the interview here: https://bit.ly/48a23ch #Biopharma #Biotech #Oncology

Hillstream BioPharma (Nasdaq: HILS) is thrilled to announce an exclusive option agreement to acquire a clinical stage asset, AV104, with a recently approved Investigational New Drug (IND) application. Hillstream intends to first seek approval of AV104 in an orphan disease for the treatment of moderate to severe cholestatic pruritis in patients with primary biliary cholangitis (PBC), a rare form of liver disease with no known cure. “The past year has been a period of transformational change for our company,” said Randy Milby, CEO of Hillstream. “This exclusive option allows the company to bring a clinical-stage asset into the organization as we shift into a patient-focused biotechnology organization. This signifies our next step as we grow into a business model focused on clinical development.” Read the details of our latest development here: https://bit.ly/3sP2UyO #Biopharma #Oncology #Biotech

Hillstream CEO Randy Milby will virtually present recent progress in targeting drug-resistant cancers at the H.C. Wainwright & Co., LLC 25th Annual Global Investment Conference today. Details may be found here: https://bit.ly/45Yac1k #Biotech #Oncology #CancerResearch #HCWCO

Hillstream BioPharma (Nasdaq: HILS) to Present at H.C. Wainwright 25th Annual Global Investment Conference on September 11th at 7:00am ET. Read the full news release here: https://bit.ly/45Yac1k #BusinessUpdate

In case you missed it: Hillstream BioPharma CEO Randy Milby recently appeared on Benzinga’s All Access show to provide updates on: - Background and experience - HSB-3215, Hillstream’s candidate for human antibodies targeting novel HER2 and HER3 - A recent collaboration with Minotaur Therapeutics and future partnership prospects - Hillstream’s scientific advisory board Tune in here: https://lnkd.in/g5UBw4rV #Oncology #CancerResearch #Biotech #Immunology